- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01246089
Ranibizumab for Myopic Neovascularization
December 31, 2013 updated by: Joao Nassaralla, Instituto de Olhos de Goiania
Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab.
ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated.
The aspect of OCT scans passing across the PM-CNV was also analyzed.
IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment.
The follow-up period was at least 6 months.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
GO
-
Goiania, GO, Brazil, 74120-050
- Instituto de Olhos de Goiania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Myopic and CNVM
Exclusion Criteria:
Patients with poor compliance
- Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (< one year). (Physician clearance was obtained for all patients).
- Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved.
- Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery.
- Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods.
- Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.
- Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ranabizumab
Myopic eyes with retinal neovascularization
|
Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2009
Primary Completion (Anticipated)
October 1, 2014
Study Completion (Anticipated)
November 1, 2014
Study Registration Dates
First Submitted
November 20, 2010
First Submitted That Met QC Criteria
November 22, 2010
First Posted (Estimate)
November 23, 2010
Study Record Updates
Last Update Posted (Estimate)
January 1, 2014
Last Update Submitted That Met QC Criteria
December 31, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Uveal Diseases
- Choroid Diseases
- Refractive Errors
- Metaplasia
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Myopia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- JN-09-2010-AR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopic Choroidal Neovascularization
-
Instituto de Olhos de GoianiaCompletedMyopic Choroidal NeovascularizationBrazil
-
AnewPharmaSuspendedMyopic Choroidal NeovascularisationChina
-
BayerCompleted
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityCompletedMyopic Choroidal NeovascularisationChina
-
Poitiers University HospitalActive, not recruiting
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...RecruitingPathological Myopic Choroidal NeovascularizationChina
-
Università degli Studi di BresciaCiro Costagliola; Francesco Semeraro; Roberto dell'Omo; Mario R Romano; Fabiana Aceto and other collaboratorsCompletedMyopic Choroidal Neovascularization | VEGF Aqueous Level | PEDF Aqueous LevelItaly
-
Sohag UniversityNot yet recruitingMyopic Choroidal Neovascularisation
-
L.V. Prasad Eye InstitutePfizerWithdrawnMyopic Choroidal Neovascular MembraneIndia
-
Hospices Civils de LyonCompletedStudy Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients (INTUITION)Idiopathic Choroidal NeovascularizationFrance
Clinical Trials on ranibizumab injection
-
Genentech, Inc.CompletedMacular Edema | Retinal Vein Occlusion
-
Genentech, Inc.CompletedMacular Edema | Retinal Vein Occlusion
-
Peter A Campochiaro, MDGenentech, Inc.CompletedMacular Edema | Retinal Vein OcclusionUnited States
-
Vista KlinikCompletedAge Related Macular Degeneration | Choroidal NeovascularizationSwitzerland
-
New England Retina AssociatesCompletedChoroidal MelanomaUnited States
-
Pusan National University HospitalNovartisCompletedExudative Age-related Macular DegenerationKorea, Republic of
-
Qena Faculty of medicine, South Valley UniversityRecruitingNon-Ischemic Central Retinal Vein Occlusion With Macular EdemaEgypt
-
St. Erik Eye HospitalUnknownBranch Retinal Vein Occlusion With Macular EdemaSweden
-
Sohag UniversityRecruiting
-
Attila VajasSemmelweis UniversityUnknown